Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing

Journal of Clinical Microbiology

Volumn 37, Issue 9, 1999, Pages 2943-2951

  Martinez Picado, Javier ^a,b,c   Sutton, Lorraine ^a   De Pasquale, Maria Pia ^a,b   Savara, Anu V ^a   D'Aquila, Richard T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c IrsiCaixa Foundation   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA; VIRUS VECTOR;

ARTICLE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0032780741     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.9.2943-2951.1999     Document Type: Article

References (36)

1. Adachi, A., H. E. Gendelman, S. Koening, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Caliendo, A. M., A. Savara, D. An, K. DeVore, J. C. Kaplan, and R. T. D'Aquila. 1996. Effects of zidovudine-selected human immunodeficiency viras type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J. Virol. 70:2146-2153.
3. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelsi, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
4. De Pasquale, M. P., R. Murphy, D. Kuritzkes, J. Martinez-Picado, J. P. Sommadossi, R. Gulik, L. Smeaton, V. DeGruttola, A. Caliendo, L. Sutton, A. V. Savara, and R. T. D'Aquila. 1998. Resistance during early virological rebound on amprenavir plus zidovudine plus lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347. Antivir. Ther. 3(Suppl. 1):50-51. (Abstract 71.)
5. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type resistance to protease inhibitors. J. Virol. 70:3763-3769.
6. Gibbs, J. S., D. A. Regier, and R. C. Desrosiers. 1994. Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retroviruses 10:343-350.
7. Haertle, T., C. J. Carrera, D. B. Wasson, L. C. Sowers, D. D. Richman, and D. A. Carson. 1988. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2′,3′-dideoxyadenosine derivatives. J. Biol. Chem. 263: 5870-5875.
8. Harada, S., Y. Koyanagi, and N. Yamamoto. 1985. Infection of HTLV-III/ LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566.
9. Havlir, D. V., C. J. Petropoulos, N. S. Hellmann, J. M. Whitcomb, D. D. Richman, and the ACTG 343. 1998. Evolution of drug resistance associated with loss of viral suppression in patients treated with indinavir, lamivudine and zidovudine. Antivir. Ther. 3(Suppl. 1):52-53. (Abstract 74.)
10. Hecht, F. M., R. M. Grant, C. J. Petropoulos, B. Dillon, M. A. Chesney, H. Tian, N. S. Hellmann, N. I. Brandrapalli, L. Digillo, B. Branson, and J. O. Kahn. 1998. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N. Engl. J. Med. 339:307-311.
11. Hertogs, K., M. P. de Bethune, V. Miller, T. Ivens, P. Schel, A. Van Cauwenberge, C. Van Den Eynde, V. Van Gerwen, H. Azijn, M. Van Houtte, F. Peeters, S. Staszewski, M. Conant, S. Bloor, S. Kemp, B. Larder, and R. Pauwels. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
12. Hirsch, M. S., B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vezinet, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, C. Loveday, J. W. Mellors, S. Vella, and D. D. Richman. 1998. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA panel. JAMA 279:1984-1991.
13. HIV sequence database. 21 May 1999, revision date. [Online.] Theoretical Biology and Biophysics Division, Los Alamos National Laboratory, Los Alamos, N.Mex. http://HIV-web.lanl.gov. [15 July 1999, last date accessed.]
14. Jackson, J. B., R. W. Coombs, K. Sannerud, F. S. Rhame, and H. H. Balfour. 1988. Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J. Clin. Microbiol. 26:1416-1418.
15. Japour, A. J., D. L. Mayers, V. A. Johnson, D. R. Kuritzkes, L. A. Beckett, J. M. Arduino, J. Lane, R. J. Black, P. S. Reichelderfer, R. T. D'Aquila, C. S. Crumpaker, The RV-43 Study Group, and The AIDS Clinical Trials Group Virology Committee Resistance Working Group. 1993. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1095-1101.
16. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
17. Martinez-Picado, J., A. Savara, L. Sutton, and R. T. D'Aquila. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:3744-3752.
18. Martinez-Picado, J., L. Sutton, A. H. Helfant, A. Savara, and R. T. D'Aquila. 1997. Novel clonal analyses of resistance to HIV-1 RT and protease inhibitors. Antivir. Ther. 2(Suppl. 5):47. (Abstract 45.)
19. Maschera, B., E. Furfine, and E. D. Blair. 1995. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69:5431-5436.
20. Mayer, K. H., S. Boswell, R. Goldstein, W. Lo, C. Xu, L. Tucker, M. P. De Pasquale, R. T. D'Aquila, and D. J. Anderson. 1999. HIV persistence in semen after adding indinavir to combination antiretroviral therapy. Clin. Infect. Dis. 28:1252-1259.
21. Miller, V., M. Sturmer, S. Staszewski, B. Groschel, K. Hertogs, M. P. de Bethune, R. Pauwels, P. R. Harrigan, S. Bloor, S. D. Kemp, and B. A. Larder. 1998. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors. AIDS 12:705-712.
22. Patick, A. K., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hermsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P. F. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
23. Pauwels, R., K. Hertogs, S. Kemp, S. Bloor, K. Van Acker, J. Hansen, W. De Beukeleer, C. Roelant, B. Larder, and P. Stoffels. 1998. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis. Antivir. Ther. 3(Suppl. 1): 35-36. (Abstract 51.)
24. Peden, K. W. 1992. Instability of HIV sequences in high copy number plasmids. J. Acquir. Immune Defic. Syndr. 5:313-315.
25. Rashtchian, A., D. M. Buchman, D. M. Schuster, and M. S. Beringer. 1992. Uracil DNA glycosylase-mediated cloning of PCR-amplified DNA: application to genomic and cDNA cloning. Anal. Biochem. 206:91-97.
26. Rashtchian, A., C. G. Thorton, and G. Heidecker. 1992. A novel method for site-directed mutagenesis using PCR and uracil DNA glycosylase. PCR Methods Appl. 2:124.
27. Ratner, L., W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, K. Baumeister, L. Ivanoff, S. R. Petteway, Jr., M. L. Pearson, J. A. Lautenberger, T. S. Papas, J. Ghrayeb, N. T. Chang, R. C. Gallo, and F. Wong-Staal. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-284.
28. Rose, R. E., Y.-F. Gong, J. A. Greytok, C. M. Bechtold, B. J. Terry, B. S. Robinson, M. Alam, R. J. Colonno, and P. F. Lin. 1996. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
29. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer, III, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
30. Shi, C., and J. W. Mellors. 1997. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 41:2781-2785.
31. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
32. Shirasaka, T., R. Yarchoan, M. C. O'Brien, R. N. Husson, B. D. Anderson, E. Kojima, T. Shimada, S. Broder, and H. Mitsuya. 1993. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. USA 90:562-566.
33. Winslow, D. L., E. D. Anton, R. A. Horlick, R. J. Zagursky, R. J. Tritch, H. Scarnati, K. Ackerman, and L. T. Bacheler. 1994. Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene. Biochem. Biophys. Res. Commun. 205:1651-1657.
34. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.
35. Zhang, D., A. M. Callendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.
36. Zhang, Y.-M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its Gag substrate cleavage sites. J. Virol. 71:6662-6670.